Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy
University of Geneva · Universitätsklinikum Tübingen
Abstract
We adoptively transferred donor-derived cytomegalovirus (CMV)-specific T-cell lines into 8 stem cell transplant recipients lacking CMV-specific T-cell proliferation. All patients, of whom one was infected by a CMV strain that was genotypically ganciclovir resistant, had received unsuccessful antiviral chemotherapy for more than 4 weeks. CMV-specific lines had been prepared by repetitive stimulation with CMV antigen, which increased the percentage of CMV-specific T cells and ablated alloreactivity completely even against patients mismatched for 1 to 3 HLA antigens. After transfer of 10(7) T cells/m(2) at a median of 120 days (range, 79-479 days) after transplantation, no side effects were noticed. Despite…
Citation impact
- FWCI
- 24.63
- Percentile
- 100%
- References
- 27
Authors
14- HEHermann EinseleCorresponding
University of Geneva, Universitätsklinikum Tübingen
- EREddy Roosnek
University of Geneva, Universitätsklinikum Tübingen
- NRNathalie Rufer
University of Geneva, Universitätsklinikum Tübingen
- CSChristian Sinzger
University of Geneva, Universitätsklinikum Tübingen
- SRSusanne Riegler
University of Geneva, Universitätsklinikum Tübingen
Topics & keywords
- Ganciclovir
- Chemotherapy
- CD8
- Cytomegalovirus
- Immunology
- Medicine
- Betaherpesvirinae
- Transplantation
- Good health and well-being